SCHEMBL15782863

SCHEMBL15782863

CCc1cc2cccc(OC)c2c(O)c1C(C)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
PPARG P37231 2/20 0.43
RXRA P19793 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
LMNA P02545 1/20 0.43
RECQL P46063 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
CYP3A4 P08684 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15782856 0.86 MAPT (0.45) MAPTLMNARECQLTAS1R3TAS1R1
SCHEMBL20020937 0.83 MAPT (0.47) MAPTPPARGRXRAPPARDPPARA
SCHEMBL15782873 0.82 MEN1 (0.50) MAPTRECQLCYP3A4MEN1KMT2A
SCHEMBL12948360 0.78 MEN1 (0.53) MAPTRECQLCYP3A4MEN1KMT2A
SCHEMBL15782875 0.75 CYP3A4 (0.44) MAPTLMNACYP3A4GAA
SCHEMBL18598736 0.74 MEN1 (0.34) MEN1KMT2A
SCHEMBL3660039 0.74 CA12 (0.55) PPARATAS1R3TAS1R1TAS1R2MEN1
SCHEMBL15782860 0.73 CA12 (0.44) MAPTMEN1KMT2ACA12CA9
SCHEMBL12800165 0.72 MEN1 (0.49) MAPTRECQLCYP3A4MEN1KMT2A
SCHEMBL24079188 0.71 PRKCI (0.46) MAPTPPARGPPARAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138831-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF President and Fellows of Harvard College (US) 2017-03-08 EP disclosed
US-20160340325-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-11-24 US disclosed
EP-1753713-B1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF HARVARD COLLEGE (US) 2016-07-27 EP disclosed
US-9365493-B2 Synthesis of tetracyclines and analogues thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-06-14 US disclosed
US-20140163238-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163238-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF TET1, TET3, MYC MAPT 990/4885PPARG 1839/4885RXRA 3458/4885
US-20160340325-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF TET1, TET3, MYC MAPT 990/4885PPARG 1839/4885RXRA 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.